One To Watch

Vanda Pharmaceuticals

Company Overview

A Washington, DC-based global biopharmaceutical company focused on developing and commercializing innovative therapies for high unmet medical needs, leveraging genetics and genomics to inform drug discovery and clinical strategy. Vanda Pharmaceuticals operates across both commercial and clinical-stage programs, with marketed products generating revenue that funds an active pipeline. The company uses pharmacogenomics to guide patient selection and clinical trial design, differentiating its development approach from conventional methods.

Headquarters and Global Presence

Vanda Pharmaceuticals is headquartered in Washington, DC, and operates as a global biopharmaceutical company with commercial and regulatory activities spanning the United States and Europe. Its European footprint was reinforced by the European Commission's approval of Hetlioz in June 2024.

Founding and History

Vanda Pharmaceuticals was founded in 2003 and listed on the Nasdaq under the ticker VNDA. The company built its commercial foundation through in-licensing agreements, acquiring rights to both tasimelteon and iloperidone through development and commercialization partnerships. A pivotal moment came in June 2024 when Novartis repurchased exclusive US and Canada commercialization and development rights to Fanapt (iloperidone) in a deal worth up to $465 million, reshaping Vanda's commercial portfolio and capital position.

Therapy Areas and Focus

Vanda's therapeutic focus spans neurology, sleep medicine, and immunology, targeting conditions with significant unmet clinical need. In sleep medicine, the company has concentrated on circadian rhythm disorders, particularly non-24-hour sleep-wake disorder, a debilitating condition prevalent in totally blind individuals. The immunology pipeline has expanded with the in-licensing of imsidolimab, broadening the company's reach into inflammatory diseases. Historically, Vanda also held commercial interests in schizophrenia through iloperidone, now reverted to Novartis.

Technology Platforms and Modalities

Vanda applies genetics and genomics technologies as core tools across drug discovery, clinical trial design, and commercial positioning. This pharmacogenomic approach enables the company to identify patient populations most likely to respond to its compounds, potentially improving clinical success rates. The platform underpins both small-molecule and biologic programs, reflecting the breadth of Vanda's pipeline strategy. By integrating genomic data into trial design, Vanda aims to build differentiated regulatory and market positioning for its assets.

Key Pipeline and Programs

Tasimelteon (Hetlioz) is Vanda's lead commercial and pipeline asset — a melatonin receptor agonist targeting MT1 and MT2 receptors, approved in the US for non-24-hour sleep-wake disorder and, as of June 2024, approved by the European Commission for the same indication in totally blind adults. The European approval marks a significant commercial expansion milestone for the product.

Imsidolimab is an anti-IL-36 receptor monoclonal antibody in-licensed from AnaptysBio under an exclusive global license covering development, manufacture, and commercialization. The asset targets IL-36 pathway-driven inflammatory conditions, with generalized pustular psoriasis among the key indications of interest. Vanda assumed full global rights, though AnaptysBio filed an anticipatory breach claim that was dismissed by the court in April 2026, affirming Vanda's license position.

Iloperidone (Fanapt), an atypical antipsychotic approved by the FDA for acute treatment of schizophrenia in adults, was the subject of a June 2024 buyback agreement under which Novartis reacquired exclusive US and Canada rights in a transaction worth up to $465 million, removing it from Vanda's active portfolio in North America.

Recent Developments

In June 2024, the European Commission approved Hetlioz (tasimelteon) for non-24-hour sleep-wake disorder in totally blind adults, extending the product's commercial reach into Europe. That same month, Novartis completed a buyback of US and Canada rights to Fanapt (iloperidone) in a deal valued at up to $465 million. Howard Pien joined Vanda's compensation committee of the executive board in June 2024, signaling continued board-level governance development. In April 2026, a court dismissed AnaptysBio's anticipatory breach claim against Vanda, affirming the validity of Vanda's exclusive global license to imsidolimab.

Key Personnel

Mihael Polymeropoulos, MD, serves as President and Chief Executive Officer; he co-founded the company and has led it since inception, bringing a background in genetics and genomics from his prior work at the National Human Genome Research Institute. James Kelly serves as Chief Financial Officer, overseeing the company's financial operations and capital allocation strategy. Howard Pien, a veteran biopharmaceutical executive with prior leadership roles at Chiron and GlaxoSmithKline, joined the compensation committee of the executive board in June 2024.

Strategic Partnerships

Vanda's commercial and pipeline portfolio has been built substantially through in-licensing, with key agreements underpinning both its marketed products and clinical programs. The AnaptysBio license grants Vanda exclusive global rights to develop, manufacture, and commercialize imsidolimab, with Guggenheim Securities and Fenwick & West advising AnaptysBio on the transaction. The June 2024 Novartis buyback of Fanapt US and Canada rights, worth up to $465 million, represents the largest single transaction in Vanda's history and restructures its commercial revenue base.

FAQ Section

The June 2024 agreement under which Novartis repurchased exclusive US and Canada commercialization and development rights to Fanapt (iloperidone) delivers up to $465 million to Vanda, substantially strengthening its balance sheet. This transaction removes a mature schizophrenia asset from Vanda's North American portfolio and redirects strategic focus toward tasimelteon and the newly licensed imsidolimab. The capital injection provides runway to advance both the European commercial launch of Hetlioz and the imsidolimab development program.

The IL-36 receptor pathway is a central driver of inflammation in conditions such as generalized pustular psoriasis, a rare and potentially life-threatening skin disease with limited approved treatment options. Imsidolimab, an anti-IL-36 receptor monoclonal antibody in-licensed from AnaptysBio, blocks this pathway upstream, offering broad anti-inflammatory activity. The mechanism addresses a genetically validated target, and Vanda's pharmacogenomic platform positions the company to refine patient selection in future trials.

Vanda integrates genetics and genomics directly into drug discovery, clinical trial design, and commercial positioning — a pharmacogenomic-first philosophy that is unusual among companies of its size. This approach is intended to identify responder populations early, reduce late-stage failure risk, and build defensible market positioning based on biological rationale. The strategy reflects the scientific background of CEO Mihael Polymeropoulos, a geneticist who conducted foundational genomics research before founding the company.

Tasimelteon is a melatonin receptor agonist targeting MT1 and MT2 receptors, approved in the US for non-24-hour sleep-wake disorder — a chronic circadian rhythm condition affecting the majority of totally blind individuals. The European Commission granted approval for the same indication in June 2024, opening a new commercial market for the product. Hetlioz represents Vanda's core revenue-generating asset and an anchor for the company's circadian biology expertise.

Vanda's pipeline spans sleep and circadian rhythm disorders, immunology, and historically psychiatry, though the schizophrenia franchise has been substantially divested following the Novartis Fanapt buyback. The forward-looking pipeline is anchored by tasimelteon in sleep medicine and imsidolimab in IL-36-driven inflammatory diseases. This dual focus on neurology/sleep and immunology reflects a deliberate broadening of the company's therapeutic base beyond its original CNS roots.

Vanda operates at a hybrid commercial and clinical-stage level: tasimelteon is fully approved in both the US and Europe, while imsidolimab is advancing through clinical development following the AnaptysBio license. The April 2026 court dismissal of AnaptysBio's anticipatory breach claim clears a legal overhang and confirms Vanda's rights to advance imsidolimab globally. Near-term milestones include the European commercial rollout of Hetlioz and clinical progress updates for imsidolimab in inflammatory indications.

Key watchpoints for Vanda include:

European commercial uptake of Hetlioz following the June 2024 EC approval, which will test the company's ex-US commercial infrastructure.
Clinical data readouts for imsidolimab in generalized pustular psoriasis and potentially other IL-36-driven indications, which will define the asset's value.
Deployment of the up-to-$465 million Novartis Fanapt proceeds — capital allocation decisions will signal management's pipeline ambitions.
Ongoing litigation risk, though the dismissal of AnaptysBio's anticipatory breach claim in April 2026 is an encouraging precedent.
Revenue concentration risk following the Fanapt divestiture, making tasimelteon's European launch performance critically important.

Want to Update your Company's Profile?